Presentation is loading. Please wait.

Presentation is loading. Please wait.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Similar presentations


Presentation on theme: "European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA."— Presentation transcript:

1 European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA Trial

2 www. Clinical trial results.org Perindopril  8 mg/day  n=6,110 Perindopril  8 mg/day  n=6,110 Placebo  n= 6,108 Placebo  n= 6,108 Endpoints (follow-up mean 3.4 years):  Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest  Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke Endpoints (follow-up mean 3.4 years):  Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest  Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke EUROPA Trial European Society of Cardiology 2003 12,218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled 12,218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled

3 www. Clinical trial results.org EUROPA Trial CV death/non-fatal MI/ cardiac arrest p=0.0003 European Society of Cardiology 2003 CV Mortality p=0.107

4 www. Clinical trial results.org EUROPA Trial Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients The present trial is the largest to show a benefit in stable, low- risk CAD patients Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients The present trial is the largest to show a benefit in stable, low- risk CAD patients


Download ppt "European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA."

Similar presentations


Ads by Google